Molly See ’23 pitched Bristol Myers Squibb (NYSE: BMY) on October 17th, 2022. Bristol Myers Squibb is a pharmaceutical company that produces life-saving drugs for critical diseases. The company was founded in 1887 in Clinton, NY, and went public on the New York Stock Exchange in 1929. Revenue is generated in one business segment, Pharmaceuticals, and operations are divided into six therapeutic areas, hematology, cardiovascular, immunology, neuroscience, fibrotic diseases, and solid tumors. The company is headquartered in New York, NY and operates globally, with a primary focus in the United States. Given the pharmaceutical industry’s inelastic demand, Bristol Myers Squibb has remained defensive in times of economic uncertainty. Molly’s investment thesis focused on their robust product line, business development initiatives, ESG focus, and ability to return capital to shareholders. SMIF voted to buy 600 shares of Bristol Myers Squibb (BMY) at market price, funded by the sale of Nike (NKE) and 200 shares of Amazon (AMZN).